While you may be going booze-free to start the year, that doesn’t mean you can’t jazz up your non-alcoholic drinks.

The new 10-year co-branded card deal with Citi, effective in 2026, is expected to boost cash remuneration by ~10% annually, ...

This was the stock's third consecutive day of gains.

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Fintel reports that on January 3, 2025, Raymond James downgraded their outlook for Vertex (NasdaqGM:VERX) from Outperform to ...

Raymond James downgraded Vertex (VERX) to Market Perform from Outperform without a price target The firm repositioned several ratings ...

Vertex (VERX – Research Report) received a Hold rating and price target from Raymond James analyst Alexander Sklar today. The company’s ...

DAR ES SALAAM: THE Bank of Tanzania’s (BoT) adjustment to the coupon rate determination method is poised to enhance investor confidence, creating a more attractive environment for fixed income ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

A member of the IBD Big Cap 20, Vertex is a top stock to consider after impressive growth last year. VERX stock could present ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...